WldS ameliorates renal injury in a type 1 diabetic mouse model

American Journal of Physiology - Renal Physiology

Volumn 306, Issue 11, 2014, Pages

  Zhu, Shuaishuai ^a   Yang, Yelin ^a   Hu, Jin ^a   Qian, Lingling ^a   Jiang, Yuchen ^a   Li, Xiaoyu ^a   Yang, Qing ^a   Bai, Hui ^a   Chen, Qi ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Diabetic renal injury; Oxidase stress; P38 and ERK

Indexed keywords

ALBUMIN; CREATININE; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; INSULIN; INTERLEUKIN 1; INTERLEUKIN 6; MITOGEN ACTIVATED PROTEIN KINASE; NICOTINAMIDE ADENINE DINUCLEOTIDE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; STREPTOZOCIN; SYNAPTOPHYSIN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DISEASE COURSE; ELECTRON MICROSCOPE; ENZYME ACTIVITY; EXPERIMENTAL MOUSE; EXTRACELLULAR MATRIX; GENE; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; INSULIN BLOOD LEVEL; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY CELL; KIDNEY INJURY; MALE; MASSON STAINING; MOUSE; NONHUMAN; OXIDATIVE STRESS; PERIODIC ACID SCHIFF STAIN; PRIORITY JOURNAL; RENAL PROTECTION; SILVER STAINING; SLOW WALLERIAN DEGENERATION GENE; STAINING; STREPTOZOTOCIN-INDUCED DIABETIC NEUROPATHY; ULTRASTRUCTURE; UREA NITROGEN BLOOD LEVEL; URINALYSIS; WESTERN BLOTTING;

DIABETIC RENAL INJURY; NAD+/NADH RATIO; OXIDASE STRESS; P38 AND ERK; WLDS;

ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 1; DIABETIC NEPHROPATHIES; INTERLEUKIN-1; INTERLEUKIN-6; KIDNEY; MALE; MICE; NERVE TISSUE PROTEINS; OXIDATIVE STRESS; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84901710494     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00418.2013     Document Type: Article

References (52)

1. Adhikary L, Chow F, Nikolic-Paterson DJ, Stambe C, Dowling J, Atkins RC, Tesch GH. Abnormal p38 mitogen-activated protein kinase signalling in human and experimental diabetic nephropathy. Diabetologia 47: 1210-1222, 2004.
2. Ahmad A, Mondello S, Di Paola R, Mazzon E, Esposito E, Catania MA, Italiano D, Mondello P, Aloisi C, Cuzzocrea S. Protective effect of apocynin, a NADPH-oxidase inhibitor, against contrast-induced nephropathy in the diabetic rat: a comparison with n-acetylcysteine. Eur J Pharmacol 674: 397-406, 2012.
3. Araki T, Sasaki Y, Milbrandt J. Increased nuclear NAD biosynthesis and SIRT1 activation prevent axonal degeneration. Science 305: 1010-1013, 2004.
4. Asaba K, Tojo A, Onozato ML, Goto A, Quinn MT, Fujita T, Wilcox CS. Effects of NADPH oxidase inhibitor in diabetic nephropathy. Kidney Int 67: 1890-1898, 2005.
5. Awazu M, Ishikura K, Hida M, Hoshiya M. Mechanisms of mitogenactivated protein kinase activation in experimental diabetes. J Am Soc Nephrol 10: 738-745, 1999.
6. Chang CC, Chang CY, Wu YT, Huang JP, Yen TH, Hung LM. Resveratrol retards progression of diabetic nephropathy through modulations of oxidative stress, proinflammatory cytokines, and AMP-activated protein kinase. J Biomed Sci 18: 47, 2011.
7. Chin BY, Mohsenin A, Li SX, Choi AM, Choi ME. Stimulation of pro-α1(I) collagen by TGF-β1 in mesangial cells: role of the p38 MAPK pathway. Am J Physiol Renal Physiol 280: F495-F504, 2001.
8. Cui XL, Douglas JG. Arachidonic acid activates c-jun N-terminal kinase through NADPH oxidase in rabbit proximal tubular epithelial cells. Proc Natl Acad Sci USA 94: 3771-3776, 1997.
9. Drel VR, Xu W, Zhang J, Pavlov IA, Shevalye H, Slusher B, Obrosova IG. Poly(adenosine 5′-diphosphate-ribose) polymerase inhibition counteracts multiple manifestations of experimental type 1 diabetic nephropathy. Endocrinology 150: 5273-5283, 2009.
10. Dronavalli S, Duka I, Bakris GL. The pathogenesis of diabetic nephropathy. Nat Clin Pract Endocrinol Metab 4: 444-452, 2008.
11. Edlund J, Fasching A, Liss P, Hansell P, Palm F. The roles of NADPH-oxidase and nNOS for the increased oxidative stress and the oxygen consumption in the diabetic kidney. Diabetes Metab Res Rev 26: 349-356, 2010.
12. Etoh T, Inoguchi T, Kakimoto M, Sonoda N, Kobayashi K, Kuroda J, Sumimoto H, Nawata H. Increased expression of NAD(P)H oxidase subunits, NOX4 and p22phox, in the kidney of streptozotocin-induced diabetic rats and its reversibility by interventive insulin treatment. Diabetologia 46: 1428-1437, 2003.
13. Ferri A, Sanes JR, Coleman MP, Cunningham JM, Kato AC. Inhibiting axon degeneration and synapse loss attenuates apoptosis and disease progression in a mouse model of motoneuron disease. Curr Biol 13: 669-673, 2003.
14. Fujii M, Inoguchi T, Sasaki S, Maeda Y, Zheng J, Kobayashi K, Takayanagi R. Bilirubin and biliverdin protect rodents against diabetic nephropathy by downregulating NAD(P)H oxidase. Kidney Int 78: 905-919, 2010.
15. Fujita H, Omori S, Ishikura K, Hida M, Awazu M. ERK and p38 mediate high-glucose-induced hypertrophy and TGF-β expression in renal tubular cells. Am J Physiol Renal Physiol 286: F120-F126, 2004.
16. Garcia Soriano F, Virag L, Jagtap P, Szabo E, Mabley JG, Liaudet L, Marton A, Hoyt DG, Murthy KG, Salzman AL, Southan GJ, Szabo C. Diabetic endothelial dysfunction: the role of poly(ADP-ribose) polymerase activation. Nat Med 7: 108-113, 2001.
17. Geiszt M, Leto TL. The Nox family of NAD(P)H oxidases: host defense and beyond. J Biol Chem 279: 51715-51718, 2004.
18. Gillingwater TH, Haley JE, Ribchester RR, Horsburgh K. Neuroprotection after transient global cerebral ischemia in Wlds mutant mice. J Cereb Blood Flow Metab 24: 62-66, 2004.
19. Gillingwater TH, Ingham CA, Parry KE, Wright AK, Haley JE, Wishart TM, Arbuthnott GW, Ribchester RR. Delayed synaptic degeneration in the CNS of Wlds mice after cortical lesion. Brain 129: 1546-1556, 2006.
20. Glass JD, Brushart TM, George EB, Griffin JW. Prolonged survival of transected nerve fibres in C57BL/Ola mice is an intrinsic characteristic of the axon. J Neurocytol 22: 311-321, 1993.
21. Ha H, Yu MR, Choi YJ, Kitamura M, Lee HB. Role of high glucoseinduced nuclear factor-kappaB activation in monocyte chemoattractant protein-1 expression by mesangial cells. J Am Soc Nephrol 13: 894-902, 2002.
22. Haneda M, Araki S, Togawa M, Sugimoto T, Isono M, Kikkawa R. Mitogen-activated protein kinase cascade is activated in glomeruli of diabetic rats and glomerular mesangial cells cultured under high glucose conditions. Diabetes 46: 847-853, 1997.
23. House AA, Eliasziw M, Cattran DC, Churchill DN, Oliver MJ, Fine A, Dresser GK, Spence JD. Effect of B-vitamin therapy on progression of diabetic nephropathy: a randomized controlled trial. JAMA 303: 1603-1609, 2010.
24. Huang JS, Chuang LY, Guh JY, Huang YJ, Hsu MS. Antioxidants attenuate high glucose-induced hypertrophic growth in renal tubular epithelial cells. Am J Physiol Renal Physiol 293: F1072-F1082, 2007.
25. Ishida T, Haneda M, Maeda S, Koya D, Kikkawa R. Stretch-induced overproduction of fibronectin in mesangial cells is mediated by the activation of mitogen-activated protein kinase. Diabetes 48: 595-602, 1999.
26. Jones SA, Hancock JT, Jones OT, Neubauer A, Topley N. The expression of NADPH oxidase components in human glomerular mesangial cells: detection of protein and mRNA for p47phox, p67phox, and p22phox. J Am Soc Nephrol 5: 1483-1491, 1995.
27. Ju KD, Shin EK, Cho EJ, Yoon HB, Kim HS, Kim H, Yang J, Hwang YH, Ahn C, Oh KH. Ethyl pyruvate ameliorates albuminuria and glomerular injury in the animal model of diabetic nephropathy. Am J Physiol Renal Physiol 302: F606-F613, 2012.
28. Kang MJ, Wu X, Ly H, Thai K, Scholey JW. Effect of glucose on stress-activated protein kinase activity in mesangial cells and diabetic glomeruli. Kidney Int 55: 2203-2214, 1999.
29. Kanwar YS, Sun L, Xie P, Liu FY, Chen S. A glimpse of various pathogenetic mechanisms of diabetic nephropathy. Annu Rev Pathol 6: 395-423, 2011.
30. Kanwar YS, Wada J, Sun L, Xie P, Wallner EI, Chen S, Chugh S, Danesh FR. Diabetic nephropathy: mechanisms of renal disease progression. Exp Biol Med (Maywood) 233: 4-11, 2008.
31. Kitada M, Kume S, Imaizumi N, Koya D. Resveratrol improves oxidative stress and protects against diabetic nephropathy through normalization of Mn-SOD dysfunction in AMPK/SIRT1-independent pathway. Diabetes 60: 634-643, 2011.
32. Lee HB, Yu MR, Yang Y, Jiang Z, Ha H. Reactive oxygen speciesregulated signaling pathways in diabetic nephropathy. J Am Soc Nephrol 14: S241-S245, 2003.
33. Lim AK, Nikolic-Paterson DJ, Ma FY, Ozols E, Thomas MC, Flavell RA, Davis RJ, Tesch GH. Role of MKK3-p38 MAPK signalling in the development of type 2 diabetes and renal injury in obese db/db mice. Diabetologia 52: 347-358, 2009.
34. Lunn ER, Perry VH, Brown MC, Rosen H, Gordon S. Absence of Wallerian degeneration does not hinder regeneration in peripheral nerve. Eur J Neurosci 1: 27-33, 1989.
35. Nangaku M. Mechanisms of tubulointerstitial injury in the kidney: final common pathways to end-stage renal failure. Intern Med 43: 9-17, 2004.
36. Sajadi A, Schneider BL, Aebischer P. Wlds-mediated protection of dopaminergic fibers in an animal model of Parkinson disease. Curr Biol 14: 326-330, 2004.
37. Sakai N, Wada T, Furuichi K, Iwata Y, Yoshimoto K, Kitagawa K, Kokubo S, Kobayashi M, Hara A, Yamahana J, Okumura T, Takasawa K, Takeda S, Yoshimura M, Kida H, Yokoyama H. Involvement of extracellular signal-regulated kinase and p38 in human diabetic nephropathy. Am J Kidney Dis 45: 54-65, 2005.
38. Samsam M, Mi W, Wessig C, Zielasek J, Toyka KV, Coleman MP, Martini R. The Wlds mutation delays robust loss of motor and sensory axons in a genetic model for myelin-related axonopathy. J Neurosci 23: 2833-2839, 2003.
39. Satoh M, Fujimoto S, Haruna Y, Arakawa S, Horike H, Komai N, Sasaki T, Tsujioka K, Makino H, Kashihara N. NAD(P)H oxidase and uncoupled nitric oxide synthase are major sources of glomerular superoxide in rats with experimental diabetic nephropathy. Am J Physiol Renal Physiol 288: F1144-F1152, 2005.
40. Shevalye H, Maksimchyk Y, Watcho P, Obrosova IG. Poly(ADPribose) polymerase-1 (PARP-1) gene deficiency alleviates diabetic kidney disease. Biochim Biophys Acta 1802: 1020-1027, 2010.
41. Shevalye H, Stavniichuk R, Xu W, Zhang J, Lupachyk S, Maksimchyk Y, Drel VR, Floyd EZ, Slusher B, Obrosova IG. Poly(ADPribose) polymerase (PARP) inhibition counteracts multiple manifestations of kidney disease in long-term streptozotocin-diabetic rat model. Biochem Pharmacol 79: 1007-1014, 2010.
42. Soldatos G, Cooper ME. Diabetic nephropathy: important pathophysiologic mechanisms. Diabetes Res Clin Pract 82, Suppl 1: S75-S79, 2008.
43. Szabo C, Biser A, Benko R, Bottinger E, Susztak K. Poly(ADP-ribose) polymerase inhibitors ameliorate nephropathy of type 2 diabetic Lepr db/db mice. Diabetes 55: 3004-3012, 2006.
44. Tojo A, Asaba K, Onozato ML. Suppressing renal NADPH oxidase to treat diabetic nephropathy. Expert Opin Ther Targets 11: 1011-1018, 2007.
45. Tsiani E, Lekas P, Fantus IG, Dlugosz J, Whiteside C. High glucoseenhanced activation of mesangial cell p38 MAPK by ET-1, ANG II, and platelet-derived growth factor. Am J Physiol Endocrinol Metab 282: E161-E169, 2002.
46. Wahlberg G, Carlson LA, Wasserman J, Ljungqvist A. Protective effect of nicotinamide against nephropathy in diabetic rats. Diabetes Res 2: 307-312, 1985.
47. Wang J, Zhai Q, Chen Y, Lin E, Gu W, McBurney MW, He Z. A local mechanism mediates NAD-dependent protection of axon degeneration. J Cell Biol 170: 349-355, 2005.
48. Wilmer WA, Dixon CL, Hebert C. Chronic exposure of human mesangial cells to high glucose environments activates the p38 MAPK pathway. Kidney Int 60: 858-871, 2001.
49. Wu J, Zhang F, Yan M, Wu D, Yu Q, Zhang Y, Zhou B, McBurney MW, Zhai Q. WldS enhances insulin transcription and secretion via a SIRT1-dependent pathway and improves glucose homeostasis. Diabetes 60: 3197-3207, 2011.
50. Xu Y, Nie L, Yin YG, Tang JL, Zhou JY, Li DD, Zhou SW. Resveratrol protects against hyperglycemia-induced oxidative damage to mitochondria by activating SIRT1 in rat mesangial cells. Toxicol Appl Pharmacol 259: 395-401, 2012.
51. Zhang S, Cai G, Fu B, Feng Z, Ding R, Bai X, Liu W, Zhuo L, Sun L, Liu F, Chen X. SIRT1 is required for the effects of rapamycin on high glucose-inducing mesangial cells senescence. Mech Ageing Dev 133: 387-400, 2012.
52. Zhu SS, Ren Y, Zhang M, Cao JQ, Yang Q, Li XY, Bai H, Jiang L, Jiang Q, He ZG, Chen Q. WldS protects against peripheral neuropathy and retinopathy in an experimental model of diabetes in mice. Diabetologia 54: 2440-2450, 2011.